On August 9, 2023, Anthony Butler, an analyst at EF Hutton, expressed his confidence in Atara Biotherapeutics (NASDAQ:ATRA) by reiterating his Buy rating and maintaining a $25 price target. This optimistic outlook suggests that Butler believes the stock has the potential for growth. However, it is worth noting that other analysts have differing price targets for ATRA. According to a survey of 7 stock analysts, the average 12-month stock price forecast for ATRA is $19.29. It is wise for investors to consult various sources of information before making any investment decisions.
Atara Biotherapeutics, Inc.
Updated on: 03/12/2023
Debt to equity ratio: Buy
Price to earnings ratio: Sell
Price to book ratio: Strong Buy
DCF: Strong Buy
ROE: Strong Sell
9:00 PM (UTC)
Date:01 December, 2023
|Analyst / firm||Rating|
ATRA Stock Performance on August 9, 2023: Volatility, Earnings Growth, and Revenue Analysis
ATRA Stock Performance on August 9, 2023
On August 9, 2023, the stock performance of Atara Biotherapeutics (ATRA) showed some volatility. The stock had a previous close of $2.25 and opened at $2.24. Throughout the day, it reached a low of $2.14 and a high of $2.36. The trading volume for the day was 952,528 shares, which is lower than the average volume of 1,713,656 shares over the past three months. The market capitalization of ATRA stands at $224.4 million.
In terms of earnings growth, ATRA had a positive growth rate of 38.36% last year. However, this year, the company experienced a decline in earnings growth, with a decrease of 11.75%. As for the next five years, there is no available data on projected earnings growth.
ATRA’s revenue growth in the previous year was impressive, with an increase of 212.55%. This indicates strong performance in generating revenue. The stock’s price-to-sales ratio is 5.26, suggesting that investors are willing to pay a premium for each dollar of sales generated by the company. The price-to-book ratio, on the other hand, is 1.73, indicating that the stock is trading at a reasonable price in relation to its book value.
The P/E ratio for ATRA is not provided (NM), which means it is not applicable or not meaningful for the company.
In terms of the stock’s performance on August 9, 2023, there were mixed results among other companies in the health technology sector. Molecular Partners A (MLLCF) had no change in its stock price, while BioXcel Therapeutics (BTAI) experienced a decrease of 1.48%. Kamada Ltd (KMDA) saw an increase of 1.75% in its stock price, and Heron Therapeutics Inc. (HRTX) had a slight decrease of 1.18%.
ATRA’s last reporting date and the EPS forecast for the current quarter are not provided. However, the company had an annual revenue of $63.6 million and a net loss of $228.3 million in the previous year. The net profit margin for ATRA is -359.12%, indicating that the company is operating at a loss.
As a healthcare technology company in the pharmaceuticals industry, ATRA does not have any executives listed. The corporate headquarters of Atara Biotherapeutics is located in Thousand Oaks, California.
In conclusion, ATRA’s stock performance on August 9, 2023, showed some fluctuations throughout the day. While the company had positive earnings growth last year, there was a decline in earnings growth this year. The revenue growth for ATRA was impressive, but the company operated at a loss with a negative net profit margin. Investors should carefully analyze these factors before making any investment decisions regarding ATRA stock.
ATRA Stock Performance Soars with High Analyst Forecasts and Positive Outlook
On August 9, 2023, Atara Biotherapeutics Inc (ATRA) experienced significant stock performance. The 12-month price forecasts from 7 analysts for ATRA had a median target of $20.00, with a high estimate of $31.00 and a low estimate of $2.00. This indicates a potential increase of 784.96% from the last recorded price of $2.26.
The consensus among 9 polled investment analysts is to buy stock in Atara Biotherapeutics Inc. This rating has remained steady since June and has not changed from a buy rating. This suggests that the company’s prospects and financial performance have been consistently positive, leading analysts to recommend buying the stock.
Atara Biotherapeutics Inc reported a loss of $0.64 per share for the current quarter. However, the company generated $7.3 million in sales during this period. The reporting date for these figures is yet to be determined.
The positive outlook from analysts and the significant increase in the 12-month price forecasts indicate that investors have high expectations for Atara Biotherapeutics Inc. The company’s potential for growth and profitability is attracting attention from the investment community.
It is important to note that stock performances can be subject to various factors and market conditions, and investors should conduct thorough research and analysis before making any investment decisions.